Showing 201-210 of 7651 results for "".
Open Access: Thoughts for the Ballot Box
https://practicaldermatology.com/topics/practice-management/open-access-thoughts-for-the-ballot-box/20908/Access to drugs, derms at stake in US presidential election.A Layered Approach to Contouring and Refilling
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-layered-approach-to-contouring-and-refilling/18611/Having moved well beyond the days when fillers could only fill in fine lines, aesthetic physicians can now help to rebuild contour, re-establish balance, and smooth out lines, says Vic Narurkar, MD, FAAD. He discusses his approach to contouring and refilling.Advances in Topical Acne Therapy
https://practicaldermatology.com/topics/practice-management/advancesin-topical-acne-therapy/21020/Even severe acne patients can be safely—and effectively—treated with topicals today.The Next Big Thing: Aesthetics in 2016
https://practicaldermatology.com/topics/practice-management/the-next-big-thing-aesthetics-in-2016/21035/Industry leaders share their predictions for what we will be talking about this year in aesthetic dermatology.Considerations for Treatment Downtime After Laser Therapy in Scar Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/considerations-for-treatment-downtime-after-laser-therapy-in-scar-repair-/18625/E. Victor Ross, MD discusses how treatment downtime influences his approach for treating scars. His goal, he said, is to achieve the highest degree of efficacy possible with laser used as mono- or combination therapy while being mindful of patients' comfort levels with the associated recovery periodEnstilar Approved; New Data for Otezla, Duac
https://practicaldermatology.com/topics/psoriasis/dermwiretv-enstilar-approved-new-data-for-otezla-duac/18687/LEO Pharma's Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% has been FDA-approved for plaque psoriasis. New data presented at EADV on Stiefel's Duac, Celgene's Otezla, and Boehringer Ingelheim's investigational biologic compound BI 655066. Plus, Galderma's OTC Excipial lOnline Marketing Tips
https://practicaldermatology.com/topics/practice-management/online-marketing-tips/18690/Risa Goldman Luksa tells you what you need to know to ensure a solid foundation for your online marketing program.The State of Academic Dermatology
https://practicaldermatology.com/topics/practice-management/the-state-of-academic-dermatology/18843/In this edition of Derm Insider, host Neal Bhatia, MD sits down with Jane Grant-Kels, MD, Sheila Fallon Friedlander, MD, and Kevin Cooper, MD to discuss the challenges and rewards of academic dermatology. From meeting aggressive budgets to dealing with EMRs, academicians face many of the same demandLet's Talk about YouTube and why your Practice should have one
https://practicaldermatology.com/topics/practice-management/let-s-talk-about-youtube-and-why-your-practice-should-have-one/19116/Any form of healthcare, dental and veterinarian practice should have a YouTube account. It is known that people prefer to watch a video to learn and understand something, rather than read an article or look at a picture. YouTube gives your practice the chance to educate your patients or clients.DermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.